Human ctla4 mutants and use thereof
US-2016017018-A1 · Jan 21, 2016 · US
Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
US9758566B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9758566-B2 |
| Application number | US-201314389013-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 28, 2013 |
| Priority date | Mar 29, 2012 |
| Publication date | Sep 12, 2017 |
| Grant date | Sep 12, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to recombinant CTLA-4 proteins, e.g., soluble CTLA-4 or CTLA-4 fusion toxins, and methods for making and using them.
First claim
Opening claim text (preview).
What is claimed is: 1. A fusion toxin comprising: a first part comprising a cytotoxic protein, and a second part comprising a non-N-glycosylated human Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4) comprising amino acids 39-152 of SEQ ID NO:1, wherein (i) the amino acid at position 113 is not Asparagine (N), and the amino acid at position 115 is neither Threonine (T) nor Serine (S); and (ii) the amino acid at position 145 is not Asparagine (N), and the amino acid at position 147 is neither Threonine (T) nor Serine (S). 2. The fusion toxin of claim 1 , wherein the cytotoxic protein comprises diphtheria toxin, Pseudomonas exotoxin, or portions or variants thereof. 3. The fusion toxin of claim 1 , further comprising a third part comprising a non-N-glycosylated human Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4). 4. The fusion toxin of claim 1 , further comprising a linker between the first and second parts. 5. A method of treating a subject who has an autoimmune disease, the method comprising administering to the subject a therapeutically effective amount of the fusion toxin of claim 1 . 6. A method of treating transplant rejection a subject who has undergone or will undergo an organ transplantation procedure, the method comprising administering to the subject a therapeutically effective amount of the fusion toxin of claim 1 . 7. A pharmaceutical composition comprising the fusion toxin of claim 1 and a physiologically acceptable carrier.
Assignees
Inventors
Classifications
- C07K14/70521Primary
CD28, CD152 · CPC title
containing a fusion with a toxin, e.g. diphteria toxin · CPC title
Drugs for immunological or allergic disorders · CPC title
from Pseudomonadaceae (F) · CPC title
containing a His-tag · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9758566B2 cover?
- This invention relates to recombinant CTLA-4 proteins, e.g., soluble CTLA-4 or CTLA-4 fusion toxins, and methods for making and using them.
- Who is the assignee on this patent?
- Massachusetts Gen Hospital
- What technology area does this patent fall under?
- Primary CPC classification C07K14/70521. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).